|Last Updated: September 20, 2020 @ 9:13 am|
|Stability:||Ambient: 2 Hour(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable|
|Interpretive Data:||General Reference Range : 0-25 U/mL|
The Roche e601 CA 15-3 electrochemiluminescent immunoassay is used. Results obtained with different methods or kits cannot be used interchangeably. The CA 15-3 assay is used to aid in the management of Stage II and III breast cancer patients. Serial testing for patient CA 15-3 assay values should be used in conjunction with other clinical methods for monitoring breast cancer. Patients with confirmed breast carcinoma frequently have CA 15-3 assay values in the same range as healthy individuals. Elevations may be observed in patients with nonmalignant disease. For these reasons, a CA 15-3 assay value, regardless of level, should not be interpreted as absolute evidence of the presence or absence of malignant disease.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with this test and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.